Eli Lilly and Company

Summary

Organization: Eli Lilly and Company
Country: USA

Top Publications

  1. pmc Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials
    Ivelina Gueorguieva
    Lilly Research Laboratories, Department of Drug Disposition, Lilly Research Laboratories, SunninghillRoad, Windlesham, Surrey, UK
    Br J Clin Pharmacol 70:523-36. 2010
  2. doi Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
    Matthew J Fell
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 326:209-17. 2008
  3. pmc Primary care physician beliefs about insulin initiation in patients with type 2 diabetes
    R P Hayes
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
    Int J Clin Pract 62:860-8. 2008
  4. doi NIR chemical imaging to guide/support BMS-561389 tablet formulation development
    L R Hilden
    Bristol Myers Squibb Co, New Brunswick, NJ 08903 0191, USA
    Int J Pharm 353:283-90. 2008
  5. ncbi In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously
    Anne B Need
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Life Sci 81:1389-96. 2007
  6. ncbi Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis
    Govinda J Weerakkody
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol Ther 12:205-12. 2007
  7. ncbi Sample size reestimation by Bayesian prediction
    Ming Dauh Wang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Biom J 49:365-77. 2007
  8. ncbi Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections
    Nancy Goebl
    Eli Lilly and Company, Drug Disposition Development Commercialization Indianapolis, IN 46285, USA
    Toxicol Pathol 35:541-8. 2007
  9. ncbi Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
    Timothy I Richardson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 17:3544-9. 2007
  10. ncbi Genetics of diabetic nephropathy: lessons from mice
    Matthew D Breyer
    Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Semin Nephrol 27:237-47. 2007

Research Grants

Detail Information

Publications62

  1. pmc Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials
    Ivelina Gueorguieva
    Lilly Research Laboratories, Department of Drug Disposition, Lilly Research Laboratories, SunninghillRoad, Windlesham, Surrey, UK
    Br J Clin Pharmacol 70:523-36. 2010
    ....
  2. doi Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
    Matthew J Fell
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 326:209-17. 2008
    ....
  3. pmc Primary care physician beliefs about insulin initiation in patients with type 2 diabetes
    R P Hayes
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
    Int J Clin Pract 62:860-8. 2008
    ..Yet, there is reluctance among physicians, specifically primary care physicians (PCPs) in the USA, to initiate insulin therapy in these patients...
  4. doi NIR chemical imaging to guide/support BMS-561389 tablet formulation development
    L R Hilden
    Bristol Myers Squibb Co, New Brunswick, NJ 08903 0191, USA
    Int J Pharm 353:283-90. 2008
    ....
  5. ncbi In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously
    Anne B Need
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Life Sci 81:1389-96. 2007
    ..Examination of LY255582 in dose-occupancy experiments demonstrated a relative order of potency of mu>kappa>delta, reproducing the previously reported order determined with in vitro binding...
  6. ncbi Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis
    Govinda J Weerakkody
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol Ther 12:205-12. 2007
    ..Regardless of the criterion, prasugrel 60 mg achieved greater IPA and fewer poor responders than the clopidogrel 300-mg LD...
  7. ncbi Sample size reestimation by Bayesian prediction
    Ming Dauh Wang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Biom J 49:365-77. 2007
    ..The method is compared with predictive power and conditional power approaches using clinical trial data. Advantages of this approach over the others are discussed...
  8. ncbi Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections
    Nancy Goebl
    Eli Lilly and Company, Drug Disposition Development Commercialization Indianapolis, IN 46285, USA
    Toxicol Pathol 35:541-8. 2007
    ....
  9. ncbi Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
    Timothy I Richardson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 17:3544-9. 2007
    ..The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation...
  10. ncbi Genetics of diabetic nephropathy: lessons from mice
    Matthew D Breyer
    Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Semin Nephrol 27:237-47. 2007
    ..In this article we review studies that have started to identify genetic risk factors for diabetic nephropathy in mice and the multiple approaches that may be used to elucidate the genetic pathogenesis of this disorder...
  11. pmc Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics
    S Thomas Forgue
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 63:24-35. 2007
    ..To evaluate the effects of gender, age, diabetes mellitus, renal and hepatic impairment on tadalafil pharmacokinetics and tolerability...
  12. ncbi Quantitative determination of peptides using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
    Jesus A Gutierrez
    Eli Lilly and Company, Indianapolis, IN, USA
    Biotechniques . 2005
    ..Coupling of this methodology to powerful analytical procedures such as immunoprecipitation is likely to lead to the rapid and reliable quantification of biologically relevant proteins and their closely related variants...
  13. ncbi Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Psychoneuroendocrinology 31:577-88. 2006
    ..Olanzapine treatment may offer sustained reduction in serum prolactin and improvement in sexual and reproductive comorbid symptoms in patients with schizophrenia who have treatment-emergent hyperprolactinemia...
  14. ncbi Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay
    Chad A Ray
    Laboratory for Experimental Medicine, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharm Biomed Anal 41:189-95. 2006
    ..The components contributing to variation within such assays have not been clearly defined. Therefore, we characterized the sources of variability within an ex vivo stimulation assay for TNF-alpha release...
  15. pmc Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Health Serv Res 8:108. 2008
    ..This study uses a US administrative claims database to evaluate the effect of AD on direct healthcare costs and utilization, and to identify the most common reasons for AD patients' emergency room (ER) visits and inpatient admissions...
  16. doi Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium"
    Eric R Siemers
    Eli Lilly and Company, Indianapolis, IN, USA
    Alzheimers Dement 4:171-3. 2008
  17. pmc Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial
    Stefan Wilhelm
    Medical Department, Lilly Deutschland GmbH, Saalburgstrasse 153, Bad Homburg, Germany
    BMC Psychiatry 8:61. 2008
    ....
  18. doi Pictet-Spengler based synthesis of a bisarylmaleimide glycogen synthase kinase-3 inhibitor
    Nicholas A Magnus
    Eli Lilly and Company, Chemical Product Research and Development Division, Indianapolis, Indiana 46285, USA
    Org Lett 12:3700-3. 2010
    ..A seven-step linear sequence that starts with commercially available 5-fluoroindole 7 affords the bisarylmaleimide 1 in 33% overall yield...
  19. doi A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?
    Chris J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    Ann Clin Biochem 47:292-300. 2010
    ..Physicians must balance the benefits and risks of treatment when determining appropriate therapy for individual patients...
  20. doi Artifactual formylation of the secondary amine of duloxetine hydrochloride by acetonitrile in the presence of titanium dioxide: implications for HPLC method development
    M J Skibic
    Eli Lilly and Company, Lilly Research Laboratories, Analytical Sciences Research and Development, Indianapolis, IN 46285, United States
    J Pharm Biomed Anal 53:432-9. 2010
    ..The artifactual reaction was effectively eliminated by changing the sample solvent to methanol and replacing sonication with shaking to aid sample dissolution...
  21. pmc The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders
    Vibeke Porsdal
    Eli Lilly Danmark A S, Nybrovej 110, DK 2800 Lyngby, Denmark
    BMC Psychiatry 10:42. 2010
    ..This observational study assessed the impact of SfW on subjective well-being, weight and waist circumference (WC)...
  22. ncbi Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database
    Karen C Holdridge
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Drug Saf 5:203-11. 2010
    ..73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone...
  23. ncbi The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension
    H Linnebjerg
    Lilly Research Center, Windlesham, Surrey, UK
    Int J Clin Pharmacol Ther 47:651-8. 2009
    ..This study evaluated the potential effect of exenatide on the pharmacokinetics and pharmacodynamics of lisinopril in patients with mild-to-moderate hypertension...
  24. doi Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Vladimir Skljarevski
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Diabetes Metab Res Rev 25:623-31. 2009
    ..To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP)...
  25. doi Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects
    Ying G Li
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Platelets 20:316-27. 2009
    ..Gender, race, body weight, and age were identified as statistically significant covariates impacting platelet inhibition...
  26. doi Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling
    Victor H Obungu
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Biochemistry 48:7251-60. 2009
    ..Furthermore, through molecular homology modeling, we have proposed a mechanism for the neutralizing activity of this antibody that involves interference with the docking of the ligand to its receptor by the antibody...
  27. doi Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool
    Chaitanya Saxena
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Proteome Res 8:3951-7. 2009
    ....
  28. doi Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder
    Rodrigo Escobar
    EU Medical, Lilly Research Laboratories, Alcobendas, Spain
    J Child Adolesc Psychopharmacol 19:253-63. 2009
    ..The aim of this study was to demonstrate the superior efficacy of atomoxetine with respect to placebo and to compare parent and child perceptions of health-related quality of life (HRQoL)...
  29. doi High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective
    Lorrene A Buckley
    Eli Lilly and Co, Indianapolis, IN 46285, USA
    Regul Toxicol Pharmacol 54:301-7. 2009
    ..g., NOAEL through a toxic dose), however, should also take into account relevance to human therapeutic doses and incorporate clinical indication- and phase-specific considerations...
  30. doi Ultrasensitive cross-species measurement of cardiac troponin-I using the Erenna immunoassay system
    A Eric Schultze
    Department of Pathology, Lilly Research Laboratories, Greenfield, Indiana 46140, USA
    Toxicol Pathol 36:777-82. 2008
    ..The Erenna system provides sensitive measurement of cTnI in rats, dogs, and monkeys, makes it possible to determine small changes from normal concentrations, and provides cTnI values from small volumes of serum...
  31. ncbi Safety and adverse event profile of duloxetine
    Joachim F Wernicke
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Expert Opin Drug Saf 4:987-93. 2005
    ..The purpose of this review is to provide an overview of some of the most important information related to safety and tolerability of duloxetine...
  32. ncbi Ototoxic occupational exposures for a stock car racing team: I. Noise surveys
    Luann E Van Campen
    Hearing Loss Prevention Team, Division of Applied Research and Technology, National Institute for Occupational Safety and Health, Cincinnati, Ohio, USA
    J Occup Environ Hyg 2:383-90. 2005
    ..Peak levels reached 140 dB SPL. NIOSH REL was exceeded for every personal noise dosimetry measurement. Recommendations for hearing protection and communication are presented...
  33. ncbi Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms)
    T A Grese
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Med Chem 44:2857-60. 2001
    ..Further elaboration of 4 into a new structural class of achiral, nonsteroidal estrogen receptor modulators is described...
  34. ncbi Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile
    F Martenyi
    Eli Lilly Regional Medical Center, Barichgasse 40 42, A 1030, Vienna, Austria
    Eur Neuropsychopharmacol 11:227-32. 2001
    ..The pharmacodynamic effect of antidepressants may also show gender differences, as suggested by reports of better response of young women to non-tricyclic antidepressants...
  35. ncbi Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine
    B J Ring
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    J Pharmacol Exp Ther 297:1044-50. 2001
    ....
  36. ncbi Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone
    M R Dossenbach
    Lilly Area Medical Center Vienna, Austria
    J Clin Psychiatry 62:28-34. 2001
    ..This multicenter, open-label study evaluated the efficacy and safety of olanzapine in patients with schizophrenia who had been nonresponsive or intolerant to a course of risperidone (mean duration of risperidone treatment = 46.3 days)...
  37. ncbi Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro
    E J Bastyr
    Eli Lilly and Company, Indianapolis, IN, USA
    Diabetes Obes Metab 2:39-46. 2000
    ..To identify factors associated with nocturnal hypoglycaemia in patients with type 2 diabetes who were new (< 2 months therapy) to insulin therapy...
  38. ncbi Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects
    D B Muchmore
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Oncologist 5:388-92. 2000
    ..This review will explore the preclinical and clinical pharmacology of raloxifene, and compare it to other SERMs currently available for clinical use...
  39. ncbi Structural relationship and desolvation behavior of cromolyn, cefazolin and fenoprofen sodium hydrates
    G A Stephenson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Int J Pharm 198:167-77. 2000
    ..Anisotropic lattice contraction is observed during dehydration of the cromolyn and cefazolin sodium and is related to the closeness of intermolecular contacts in the hydrated structures...
  40. ncbi Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats
    C K Jones
    Program of Medical Neurobiology, Indiana University School of Medicine, IN, USA
    Eur J Pharmacol 391:105-12. 2000
    ..However, these three neurotransmitter systems appear to modulate different aspects of prepulse inhibition...
  41. ncbi Safety of inhaled proteins for therapeutic use
    R K Wolff
    Toxicology Research Labs, Lilly Research Laboratory, Greenfield, IN 46140, USA
    J Aerosol Med 11:197-219. 1998
    ..Although the safety information is relatively sparse at present, the available data suggest that the inhalation route can be an attractive route to consider for many therapeutic proteins...
  42. ncbi Aminoglycoside neurotoxicity involves NMDA receptor activation
    J A Segal
    Laboratory of Neuroscience, National Institute on Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Brain Res 815:270-7. 1999
    ..Moreover, aminoglycosides may damage the central nervous system in individuals with compromised blood brain barriers...
  43. ncbi Development of in vitro peptide substrates for human rhinovirus-14 2A protease
    Q M Wang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA
    Arch Biochem Biophys 356:12-8. 1998
    ..Our data indicated that these fluorescent peptide substrates were suitable for 2A protease characterization and inhibitor evaluation...
  44. ncbi Determination of LY355703 in dog and mouse plasma by positive ion liquid chromatography/tandem mass spectrometry with atmospheric pressure chemical ionization
    M Berna
    Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Mass Spectrom 33:138-43. 1998
    ..7 to 7.6% and from 4.8 to 4.5%, respectively. Throughput is approximately one sample every 3 min. This assay is simple, sensitive, accurate, precise and is being used to support toxicokinetic studies in dog and mouse...
  45. ncbi Nicotine withdrawal leads to increased sensitivity of serotonergic neurons to the 5-HT1A agonist 8-OH-DPAT
    K Rasmussen
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 133:343-6. 1997
    ....
  46. ncbi Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation
    Y L Ma
    Gene Regulation, Bone and Inflammation Research Division, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    Endocrinology 142:4047-54. 2001
    ..We propose that the rapid and sustained increase in RANKL and decrease in OPG initiate maintain and favor the cascade of events in the differentiation/recruitment and activation of osteoclasts...
  47. ncbi The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease
    J S Kennedy
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Int J Geriatr Psychiatry 16:S24-32. 2001
    ..In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment...
  48. ncbi Environmental fate and chemistry of raloxifene hydrochloride
    Jerold Scott Teeter
    Lilly Research Laboratories, Division of Eli Lilly and Company, Greenfield, Indiana 46140, USA
    Environ Toxicol Chem 21:729-36. 2002
    ..0188/d and 37 d, respectively. Given the fate and behavior of raloxifene in these studies, it is anticipated that raloxifene would rapidly dissipate in the environment...
  49. ncbi Use of a five-channel multiplexed electrospray quadrupole time-of-flight hybrid mass spectrometer for metabolite identification
    Laurent Leclercq
    Drug Disposition Department, Lilly Development Center, Mont Saint Guibert, Belgium
    Rapid Commun Mass Spectrom 19:1611-8. 2005
    ..The paper also focuses on the advantages and disadvantages of this new approach compared to other approaches in the literature in the field of metabolite identification...
  50. ncbi 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents
    José A Martín
    Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly S A, Alcobendas 28108, Madrid, Spain
    Bioorg Med Chem Lett 15:51-5. 2005
    ..Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes...
  51. ncbi Ion channels in drug discovery and development
    Emanuele Sher
    Eli Lilly and Co, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
    Expert Opin Investig Drugs 13:1651-4. 2004
    ..Finally, cardiac ion channel liability, in the context of drug discovery and development, was thoroughly discussed...
  52. ncbi ATP-sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1-/- mouse alpha-cells
    Jesper Gromada
    Lilly Research Laboratories, Essener Strasse 93, D 22419 Hamburg, Germany
    Diabetes 53:S181-9. 2004
    ....
  53. ncbi Beyond skin color: emerging roles of melanin-concentrating hormone in energy homeostasis and other physiological functions
    Yuguang Shi
    Endocrine Research, Lilly Research Laboratories, DC 0545, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Peptides 25:1605-11. 2004
    ..This review focuses on emerging roles of MCH in regulating central and peripheral mechanisms...
  54. ncbi Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters
    Anne H Dantzig
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Biochem Pharmacol 67:1111-21. 2004
    ..Unlike murine mrp1, both orthologs were photolabeled well by LY475776. These studies indicate that the specificity of LY475776 is fairly limited to Pgp and MRP1 and further studies will help to define the binding regions...
  55. ncbi Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis IN 46285, USA
    J Clin Psychopharmacol 24:30-5. 2004
    ..It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued...
  56. ncbi Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years
    Peter D Feldman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 64:998-1004. 2003
    ..This analysis compares the efficacy of risperidone and olanzapine in controlling negative and positive symptoms of chronic psychosis in older patients...
  57. ncbi A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis
    Jozef Haczynski
    Medical Department Eli Lilly Polska, Warsaw, Poland
    Med Sci Monit 9:PI29-35. 2003
    ..Two antibiotic suspensions, cefaclor (CEF) and amoxicillin/clavulanate (AMC), are commonly used in Poland for the treatment of PT caused by GABHS in children...
  58. ncbi Receptor-based design of cytokine therapeutics
    A B Shanafelt
    BioResearch Technologies and Proteins, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Pharm Biotechnol 4:1-20. 2003
    ..The clinical success enjoyed by a subset of these proteins signals the advent of a new mode of therapeutic protein development...
  59. ncbi Kinases as therapeutic targets for heart failure
    Chris J Vlahos
    Cardiovascular Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Rev Drug Discov 2:99-113. 2003
  60. ncbi Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine
    Sandra A Filla
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA
    J Med Chem 45:4383-6. 2002
    ..These data suggest that a GluR5 kainate receptor antagonist might be an efficacious antimigraine therapy with a novel mechanism of action...
  61. ncbi Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial
    Madhav A Namjoshi
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN, USA
    J Affect Disord 69:109-18. 2002
    ..The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania...
  62. pmc Increased production of low molecular weight recombinant proteins in Escherichia coli
    R M Belagaje
    Department of Biotechnology, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Protein Sci 6:1953-62. 1997
    ..Furthermore, highly produced insulin-like growth factor-1 derivatives and human proinsulin analogs are converted to their natural sequences by removal of dipeptides with cathepsin C...

Research Grants26

  1. REGULATION OF NA+ OF ABSORPTION ON RENAL PGE2 RECEPTORS
    Matthew Breyer; Fiscal Year: 2003
    ..Finally we will characterize the functional consequences of over-expressing the collecting duct EP4 receptor in a transgenic mouse. These studies should help elucidate the role of EP receptors in renal Na+ homeostasis. ..
  2. Cyclooxygenase Stimulated Neovascularization in Diabetic
    Matthew Breyer; Fiscal Year: 2006
    ..Pozzi's expertise in angiogenesis and Dr. Breyer's expertise in mouse models of diabetic nephropathy, and draws on their common interest in the prostanoid pathway in cell differentiation and survival. ..
  3. Regulation of Renal Function by PGE2 and PGF2a Receptors
    Matthew Breyer; Fiscal Year: 2006
    ..Through these studies we hope to identify the pathway through which suppression of prostanoid products by cyclooxygenase inhibitors results in sodium retention. ..
  4. MOLECULAR TARGETS REGULATING APOPTOSIS
    MYRTLE DAVIS; Fiscal Year: 2001
    ..Furthermore, since these studies will be significant in the elucidation of mechanisms for induction of apoptosis, they may provide a means by which tumor cells expressing ras oncogene can be selectively targeted. ..
  5. TAT ASSOCIATED KINASE REGULATION OF HIV GENE EXPRESSION
    Richard Gaynor; Fiscal Year: 2000
    ..Develop a reconstituted in vitro transcription system in which tat activation is dependent on the addition of the tat-associated kinase and further to determine the role of this kinase on regulating in vivo HIV-1 gene expression. ..
  6. Mechanisms regulating HIV-1 gene expression
    Richard Gaynor; Fiscal Year: 2001
    ..These studies will address the different mechanisms involved in regulating the ability of Tat to activate HIV- 1 gene expression. ..